var

2 scientist jobb hittade för dig i mölndal, västra götalands län.

filtrering1
filtrering:
1plats
jobbtyp
yrkesområde
alla filter
valda filter:
mölndal, västra götalands län
rensa sökning
valda filter:
mölndal, västra götalands län
rensa sökning
    • mölndal, västra götalands län
    • konsultuppdrag
    AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. AstraZeneca is proud to offer a unique workplace culture that inspires innovation and collaboration. Co-workers are empowered to express diverse perspectives - and are made to feel valued, energized and rewarded for their ideas and creativity.We are currently looking
    AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. AstraZeneca is proud to offer a unique workplace culture that inspires innovation and collaboration. Co-workers are empowered to express diverse perspectives - and are made to feel valued, energized and rewarded for their ideas and creativity.We are currently looking
    • göteborg, västra götalands län
    • konsultuppdrag
    Are you an ADME specialist and DMPK project team lead? We are now looking for a new team member for our client IRLAB Therapeutics AB in Gothenburg. IRLAB Therapeutics is a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease. Their drug portfolio comprises two Phase IIb drug candidates, two preclinical candidates preparing for Phase I studies, and a well-advanced
    Are you an ADME specialist and DMPK project team lead? We are now looking for a new team member for our client IRLAB Therapeutics AB in Gothenburg. IRLAB Therapeutics is a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease. Their drug portfolio comprises two Phase IIb drug candidates, two preclinical candidates preparing for Phase I studies, and a well-advanced